Oragenics Inc (OGEN.A) Quote| Reuters.com
United States

Oragenics Inc (OGEN.A)

OGEN.A on American Stock Exchange

30 Jun 2016
Change (% chg)

$0.01 (+1.63%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for OGEN.A


Oragenics, Inc. develops, markets and sells probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. The Company is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. It is engaged in developing its antibiotic... (more)
No analyst recommendations are available for OGEN.A.


Beta: 1.93
Market Cap(Mil.): $20.43
Shares Outstanding(Mil.): 40.06
Dividend: --
Yield (%): --


  OGEN.A Industry Sector
P/E (TTM): -- 34.76 35.71
EPS (TTM): -0.34 -- --
ROI: -207.52 15.00 14.23
ROE: -207.52 16.06 15.43

BRIEF-Oragenics says to sell consumer probiotic business

* Oragenics announces entry into definitive agreement to sell consumer probiotic business

Jun 23 2016

BRIEF-Oragenics Inc says Alan Joslyn to be new president and CEO

* Oragenics announces new president, chief executive officer and member of the board of directors

Jun 06 2016

BRIEF-Oragenics announces results from confirmatory animal study of Ag013

* Oragenics Announces Positive Results From Confirmatory Animal Study Of Ag013 For Treatment Of Oral Mucositis And Plans To Finalize Phase 2 Clinical Trial Protocol

May 02 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Pechala's Reports
Provider : Reuters Investment Profile
Provider : Wright Reports
Provider : Sadif Analytics Prime
Provider : Sadif Analytics Prime

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.